Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study

Campello, Elena; Radu, Cm; Tonello, Marta; Kuzenko, Anna; Bulato, Cristiana; Hoxha, Ariela; Mattia, Elena De; Spiezia, Luca; Ruffatti, Amelia; Simioni, Paolo

doi:10.1080/03009742.2017.1372518

Cited by 5 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies investigating EVs in APS patients with a history of obstetric complications enrolled either pregnant [ 83 , 84 , 85 ] or non-pregnant APS patients [ 69 , 86 ]. In one study of non-pregnant obstetric APS patients, increased levels of total EVs were observed compared to healthy non-pregnant women [ 86 ]; however, in another study, Breen et al did not detect increases in specific EVs populations, endothelial (CD51+ or CD105+) and platelet (CD41+ or CD61+), between the two groups [ 69 ].…”

Section: Extracellular Vesicles In Antiphospholipid Syndromementioning

confidence: 99%

“…Levels of endothelial EVs were increased in all trimesters of obstetric APS patients compared to healthy pregnant women. Levels of platelet EVs were not increased in the first [ 84 , 85 ] and second trimester, but were shown to be increased in the third trimester obstetric APS patients compared to healthy pregnant women [ 84 ] ( Table 3 ).…”

Section: Extracellular Vesicles In Antiphospholipid Syndromementioning

confidence: 99%

“…Levels of coagulation molecules and molecules involved in angiogenesis expressed on EVs have been investigated on EVs from obstetric APS patients. Levels of PS- and endoglin-positive EVs were increased in the obstetric APS patients in their first and second trimesters compared to healthy pregnant women, and TF was additionally expressed on EVs from obstetric APS patients in the third trimester compared to healthy pregnant women [ 84 ]. Levels of endoglin- and TF-positive EVs as well as platelet EVs were increased in pregnant obstetric APS patients at high risk (triple aPL positive) compared to low risk (single aPL positive).…”

Section: Extracellular Vesicles In Antiphospholipid Syndromementioning

confidence: 99%

See 2 more Smart Citations

Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges

Štok

Čučnik

Sodin‐Šemrl

et al. 2021

IJMS

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thromboembolism, obstetric complications, and the presence of antiphospholipid antibodies (aPL). Extracellular vesicles (EVs) play a key role in intercellular communication and connectivity and are known to be involved in endothelial and vascular pathologies. Despite well-characterized in vitro and in vivo models of APS pathology, the field of EVs remains largely unexplored. This review recapitulates recent findings on the role of EVs in APS, focusing on their contribution to endothelial dysfunction. Several studies have found that APS patients with a history of thrombotic events have increased levels of EVs, particularly of endothelial origin. In obstetric APS, research on plasma levels of EVs is limited, but it appears that levels of EVs are increased. In general, there is evidence that EVs activate endothelial cells, exhibit proinflammatory and procoagulant effects, interact directly with cell receptors, and transfer biological material. Future studies on EVs in APS may provide new insights into APS pathology and reveal their potential as biomarkers to identify patients at increased risk.

show abstract

Section: Extracellular Vesicles In Antiphospholipid Syndromementioning

confidence: 99%

Section: Extracellular Vesicles In Antiphospholipid Syndromementioning

confidence: 99%

Section: Extracellular Vesicles In Antiphospholipid Syndromementioning

confidence: 99%

See 1 more Smart Citation

Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges

Štok

Čučnik

Sodin‐Šemrl

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…96 Supporting this proposal, many authors reported increased amounts of plasma MPs in APS patients. [19][20][21][22]97 The vesicles with increased numbers are consistently found to be of endothelial origin. Nevertheless, in some cases, increased amounts of platelet and monocyte MPs have also been found in APS patients compared with healthy controls.…”

Section: Microparticles Constitute a Versatile Signaling Mechanism Which Is Also Related To Procoagulant Statesmentioning

confidence: 99%

Microparticles: An Alternative Explanation to the Behavior of Vascular Antiphospholipid Syndrome

Álvarez

Rúa

2021

Semin Thromb Hemost

View full text Add to dashboard Cite

Antiphospholipid syndrome is an autoimmune disease characterized by the persistent presence of antiphospholipid antibodies, along with occurrence of vascular thrombosis and pregnancy morbidity. The variety of antiphospholipid antibodies and their related mechanisms, as well as the behavior of disease in wide groups of patients, have led some authors to propose a differentiation of this syndrome into two independent entities: vascular and obstetric antiphospholipid syndrome. Thus, previous studies have discussed whether specific autoantibodies may be responsible for this differentiation or, in contrast, how the same antibodies are able to generate two different clinical presentations. This discussion is yet to be settled. The capability of serum IgG from patients with vascular thrombosis to trigger the biogenesis of endothelial cell-derived microparticles in vitro is one of the previously discussed differences between the clinical entities of antiphospholipid syndrome. These vesicles constitute a prothrombotic mechanism as they can directly lead to clot activation in murine models and recalcified human plasma. Nevertheless, other indirect mechanisms by which microparticles can spread a procoagulant phenotype could be critical to understanding their role in antiphospholipid syndrome. For this reason, questions regarding the cargo of microparticles, and the signaling pathways involved in their biogenesis, are of interest in attempting to explain the behavior of this autoimmune disease.

show abstract

“…One study did not include a healthy pregnant control group (Abolbaghaei et al, 2021). Pathologies included were: pre-eclampsia (PE; n = 27) (Alasztics et al, 2021;Alijotas et al, 2012;Campello et al, 2015;Dragovic et al, 2013;Hu et al, 2018;Jadli et al, 2017;Kovács et al, 2018aKovács et al, , 2018bLalic-Cosic et al, 2021;León et al, 2021;Li et al, 2020;Lok et al, 2007Lok et al, , 2008Lok et al, , 2009bMaduray et al, 2020;Marques et al, 2012;Mikhailova et al, 2014;Murugesan et al, 2022;Pillay et al, 2016Pillay et al, , 2020Textoris et al, 2013;Truong et al, 2017;VanWijk et al, 2002a;Verma et al, 2018;Wang et al, 2020;Weingrill et al, 2021;Zhang et al, 2018), small for gestational age/fetal growth restriction/intrauterine growth restriction (SGA/FGR/IUGR; n = 5) (Alijotas et al, 2012;Bretelle et al, 2003;Jadli et al, 2017;Li et al, 2020;Miranda et al, 2018), pre-term birth or premature preterm rupture of membranes (PTB/PPROM; n = 4) (Menon et al, 2020;Menon, Debnath et al, 2019;Tronco et al, 2020;Truong et al, 2017) (Pillay et al, 2020), HIV with or without malaria (n = 1) (Moro et al, 2016) and anti-phospholipid syndrome (APS; n = 1) (Campello et a...…”

Section:  Circulating Evs In Pregnancy Pathologiesmentioning

confidence: 99%

Circulating extracellular vesicles in healthy and pathological pregnancies: A scoping review of methodology, rigour and results

Barnes,

Pantazi,

Holder

2023

J of Extracellular Vesicle

View full text Add to dashboard Cite

Extracellular vesicles (EVs) play a crucial role in pregnancy, revealed by the presence of placental‐derived EVs in maternal blood, their in vitro functionality, and their altered cargo in pregnancy pathologies. These EVs are thought to be involved in the development of pregnancy pathologies, such as pre‐eclampsia, pre‐term birth, and fetal growth restriction, and have been suggested as a source of biomarkers for gestational diseases. However, to accurately interpret their function and biomarker potential, it is necessary to critically evaluate the EV isolation and characterization methodologies used in pregnant cohorts. In this systematic scoping review, we collated the results from 152 studies that have investigated EVs in the blood of pregnant women, and provide a detailed analysis of the EV isolation and characterization methodologies used. Our findings indicate an overall increase in EV concentrations in pregnant compared to non‐pregnant individuals, an increased EV count as gestation progresses, and an increased EV count in some pregnancy pathologies. We highlight the need for improved standardization of methodology, greater focus on gestational changes in EV concentrations, and further investigations into the functionality of EVs. Our review suggests that EVs hold great promise as diagnostic and translational tools for gestational diseases. However, to fully realize their potential, it is crucial to improve the standardization and reliability of EV isolation and characterization methodologies, and to gain a better understanding of their functional roles in pregnancy pathologies.

show abstract

Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study

Cited by 5 publications

References 9 publications

Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges

Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges

Microparticles: An Alternative Explanation to the Behavior of Vascular Antiphospholipid Syndrome

Circulating extracellular vesicles in healthy and pathological pregnancies: A scoping review of methodology, rigour and results

Contact Info

Product

Resources

About